LP
Therapeutic Areas
Bicara Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BCA101 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1/2 |
Leadership Team at Bicara Therapeutics
CM
Claire Mazumdar
Chief Executive Officer
MV
Mark Velleca
Chief Scientific Officer
DD
David Donabedian
Chief Technology Officer
MK
Michele Korfin
Chief Operating and Financial Officer
KB
Kevin Bitterman
Chairman of the Board
CR
Carlo Rizzuto
Board Member
RG
Robert Gottlieb
Board Member
RS
Rajeev Shah
Board Member
BP
Boris Peaker
Board Member
RS
Robert Schreiber
Scientific Advisory Board Member